BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Mistral Pharma Inc. Files a Notice of Intention Under Bankruptcy and Insolvency Act


6/13/2008 2:55:58 PM

MONTREAL, QUEBEC--(MARKET WIRE)--Jun 13, 2008 -- Mistral Pharma Inc. (CDNX:MIP.V - News) (the "Corporation"), announces that earlier today, it filed a notice of intention to make a proposal to its creditors under the Bankruptcy and Insolvency Act. The Corporation filed the notice in order to facilitate ongoing negotiations concerning the terms and conditions of purchase offers for its business and assets it has received from potential acquirors.

If agreed upon, it is intended that the purchase offers will be part of the Corporation's proposal and will be subject to a vote at a meeting of its creditors to be held at a date to be determined. The Corporation has retained the firm of Demers Beaulne to act as trustee in bankruptcy.

In the meantime, the Corporation will benefit from a complete stay with regards to debt payments and to any possible creditor's proceedings.

In order to be accepted, the Corporation's proposal will need to be approved by creditors representing the majority in number and at least 66.66% in value of the Corporation's debt.

Forward-looking Statements

Except for historical information provided herein, this press release may contain information and statements of a forward-looking nature concerning the future performance of Mistral Pharma. These statements are based on assumptions and uncertainties as well as on management's best possible evaluation of future events. Such factors may include, without excluding other considerations, fluctuations in quarterly results, evolution in customer demand for Mistral Pharma's products, the impact of price pressures exerted by competitors, and general market trends or economic changes. As a result, readers are advised that actual results may differ from expected results.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release. Contact: Contacts: Mistral Pharma Inc. Bertrand F. Bolduc, B.Pharm., MBA President and Chief Executive Officer 514-421-1717 #2224 bbolduc@mistralpharma.com

Mistral Pharma Inc. Alain Provencher, CA, CF Vice-President and Chief Financial Officer 514-421-1717 #2222 aprovencher@mistralpharma.com

Source: Mistral Pharma Inc.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES